$ENTX

Entera Bio (ENTX) appointed Juan Camilo Arjona Ferreira as a director and compensation committee member, effective December 1, 2026. Haya Taitel will step down from the board on the same date. Ferreira has over 20 years of global clinical development experience and is currently Organon’s Head of R&D and Chief Medical Officer.

Entera Bio Ltd. (ENTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN) He joins Entera with two d

Alignment Healthcare (ALHC) shares dropped 24.2% to $6.60 in pre-market trading after its largest California contract was downgraded to 3.5 stars, making it ineligible for bonus payments. Several other stocks also fell, including Entera Bio (ENTX), AT&T (T), Verizon (VZ), and RenX Enterprises (RENX).

Entera Bio (ENTX) will present Phase 3 trial design for its oral osteoporosis drug, EB613, at a conference in October 2026. The study will evaluate EB613 in postmenopausal women with osteoporosis. The company previously reported positive Phase 2 results, showing improvements in bone density and markers. EB613 is an oral, once-daily tablet, unlike current anabolic therapies that require injections.

Entera Bio Ltd. (ENTX) appointed Laura Hamill to its Board of Directors, effective December 1, 2026. Hamill has 35 years of biopharmaceutical experience, including roles at Gilead and Amgen. She succeeds Yonatan Malca, who is stepping down. Hamill's expertise is expected to support Entera's late-stage clinical trials and commercial readiness for EB613, an oral peptide for osteoporosis.

Entera Bio (ENTX) received an 'Outperform' rating and $9 price target from Leerink Partners. The company's lead drug, EB613, is in development for osteoporosis and has completed Phase 2 trials. Entera recently raised $275M in funding and plans to initiate Phase 3 trials in late 2026, with data expected in 2028. ENTX was trading at $3.03 per share as of September 17, 2026.

Entera Bio (ENTX) raised $275M in an oversubscribed private placement, funding Phase 3 trials for EB613, its oral osteoporosis treatment, and extending its cash runway to 2030. Shares rose despite dilution concerns, with BVF Partners leading the investment. The FDA accepted the Phase 3 protocol, and analysts project a loss for Q2 2024 with a $9 price target.

Entera Bio Ltd. (NASDAQ: ENTX) reported Q2 2026 EPS loss of $0.14 versus a $0.08 consensus estimate, with net loss widening to $7.3 million from $2.7 million a year earlier, driven mainly by a $2.7 million non-cash warrant fair value remeasurement. The company also closed an oversubscribed $275 million private placement to fund EB613 Phase 3 NDA work through 2030.

Entera Bio Ltd. (ENTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Entera Announces Second Quarter 2026 Financial Results and Business Updates U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women wi

Entera Bio Ltd. (ENTX) disclosed in an SEC Schedule 13G that Longitude Venture Partners V, L.P. (via Longitude Capital Partners V, LLC and its managing members) is the record holder of 7,843,138 ordinary shares, or 4.6% of 172,251,411 shares outstanding as of July 28, 2026. The filing also references Seven Fleet’s potential 4.1% beneficial ownership.